Physician profile
Peter H Lee
NPI 1932237013
$28,309.33
in general payments reported to CMS, 2019-2025
30 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $5,331 · 2021: $725 · 2022: $1,027 · 2023: $971 · 2024: $1,069 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,373 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,373.38 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $21,088.59 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,027.58 | 2021-2025 | |
| Akebia Therapeutics INC | $849.21 | 2020-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals Lp | $735.18 | 2019-2025 | Lokelma, Farxiga |
| Ardelyx, INC. | $677.77 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $659.46 | 2019-2025 | Repatha, Krystexxa |
| Vifor Pharma, INC. | $621.00 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $381.41 | 2019-2023 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.91 | 2023-2025 | Jardiance |
| Boston Scientific Corporation | $250.71 | 2025 | Axios, Overstitch Endoscopic Suturing System |
| Mallinckrodt Hospital Products INC. | $234.18 | 2021-2024 | Acthar |
| Horizon Therapeutics Plc | $160.78 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $152.42 | 2023-2025 | |
| Travere Therapeutics, INC. | $150.32 | 2023 | |
| Mallinckrodt Enterprises LLC | $147.14 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $127.15 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $111.45 | 2023 | Jesduvroq |
| Alexion Pharmaceuticals, INC. | $110.44 | 2019 | |
| Jazz Pharmaceuticals INC. | $109.50 | 2019 | |
| Fresenius USA Marketing, INC. | $97.46 | 2019 | |
| Calliditas Therapeutics US INC. | $70.93 | 2022 | |
| Baxter Healthcare | $70.00 | 2019 | |
| Lilly USA, LLC | $34.49 | 2024 | Jardiance |
| Nuwellis, INC. | $30.28 | 2021 | |
| Kyowa Kirin, INC. | $29.43 | 2022 | |
| Abbvie INC. | $25.00 | 2020 | |
| Merck Sharp & Dohme LLC | $19.72 | 2019 | |
| Novo Nordisk INC | $16.98 | 2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $12.58 | 2019 | |
| Dentsply Sirona INC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.